Literature DB >> 9497946

Neuroleptic malignant syndrome in the acquired immunodeficiency syndrome.

J L Hernández1, L Palacios-Araus, S Echevarría, A Herrán, J F Campo, J A Riancho.   

Abstract

Patients infected by the human immunodeficiency virus are predisposed to many infectious and noninfectious complications and often receive a variety of drugs. Furthermore, they seem to have a particular susceptibility to idiosyncratic adverse drug reactions. It is therefore surprising that only a few cases of the neuroleptic malignant syndrome have been described in patients with the acquired immunodeficiency syndrome. A high index of suspicion is required to diagnose the neuroleptic malignant syndrome in these patients, as its usual manifestations, including fever and altered consciousness, are frequently attributed to an underlying infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9497946      PMCID: PMC2431511          DOI: 10.1136/pgmj.73.866.779

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  28 in total

Review 1.  Pathophysiology and management of the serotonin syndrome.

Authors:  T M Brown; B P Skop; T R Mareth
Journal:  Ann Pharmacother       Date:  1996-05       Impact factor: 3.154

2.  Neuroleptic malignant syndrome in an AIDS patient.

Authors:  E A Burch; J Montoya
Journal:  J Clin Psychopharmacol       Date:  1989-06       Impact factor: 3.153

Review 3.  Neuroleptic malignant syndrome.

Authors:  J L Levenson
Journal:  Am J Psychiatry       Date:  1985-10       Impact factor: 18.112

4.  Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome--a possible link?

Authors:  D Ames; W C Wirshing
Journal:  JAMA       Date:  1993-02-17       Impact factor: 56.272

5.  Electroconvulsive Therapy in the Treatment of the Neuroleptic Malignant Syndrome.

Authors:  John M. Davis; Philip G. Janicak; Paul Sakkas; Cindy Gilmore; Zhengyu Wang
Journal:  Convuls Ther       Date:  1991

Review 6.  The neurologic complications of human immunodeficiency virus infection.

Authors:  J R Berger; R M Levy
Journal:  Med Clin North Am       Date:  1993-01       Impact factor: 5.456

7.  Spectrum concept of neuroleptic malignant syndrome.

Authors:  S Singh; G Singh; S Ong
Journal:  Br J Psychiatry       Date:  1988-07       Impact factor: 9.319

8.  Neuroleptic malignant syndrome in a patient with acquired immunodeficiency syndrome.

Authors:  W B Bernstein; B Scherokman
Journal:  Acta Neurol Scand       Date:  1986-06       Impact factor: 3.209

Review 9.  The neuroleptic malignant syndrome: agent and host interaction.

Authors:  A Shalev; H Munitz
Journal:  Acta Psychiatr Scand       Date:  1986-04       Impact factor: 6.392

10.  Rhabdomyolysis and hyperthermia after cocaine abuse: a variant of the neuroleptic malignant syndrome?

Authors:  M Daras; L Kakkouras; A J Tuchman; B S Koppel
Journal:  Acta Neurol Scand       Date:  1995-08       Impact factor: 3.209

View more
  3 in total

Review 1.  Neurobehavioral Manifestations of Human Immunodeficiency Virus/AIDS: Diagnosis and Treatment.

Authors:  Elyse J Singer; April D Thames
Journal:  Neurol Clin       Date:  2016-02       Impact factor: 3.806

Review 2.  Neuroleptic malignant syndrome: an easily overlooked neurologic emergency.

Authors:  Ramadhan Oruch; Ian F Pryme; Bernt A Engelsen; Anders Lund
Journal:  Neuropsychiatr Dis Treat       Date:  2017-01-16       Impact factor: 2.570

3.  Case Report: Neuroleptic malignant syndrome in a HIV-positive patient.

Authors:  Sibi Joseph; Jerry George; Mongezi Tau; Lourdes de Fatima Ibanez-Valdes; Thozama Dubula; Humberto Foyaca-Sibat
Journal:  F1000Res       Date:  2020-11-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.